Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Recruiting 85Active not recruiting 47Completed 23Not yet recruiting 13Terminated 9Withdrawn 3Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 28Neoplasms 26Prostatic Neoplasms 22Colorectal Neoplasms 17Head and Neck Neoplasms 14Pancreatic Neoplasms 11Lung Neoplasms 10Brain Neoplasms 10Neoplasm Metastasis 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma 7Glioblastoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid, Acute 5Leukemia 5Kidney Neoplasms 5Hematologic Neoplasms 5Sarcoma 4Liver Neoplasms 4

Interventions

venetoclax 1fludarabine phosphate 1Rituximab 1Cyclophosphamide 1CT-P10 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Burkitt Lymphoma × 1 year × Clear all
NCT07196111 2026-05-28

BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors

Guangzhou Bio-gene Technology Co., Ltd

Phase EARLY_PHASE1 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma

NCT04285268 2026-01-30

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06009107 2025-08-08

B-ALL

Juventas Cell Therapy Ltd.

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡